175 related articles for article (PubMed ID: 29935685)
1. Techniques and Safety Issues for Intraperitoneal Chemotherapy.
González-Moreno S; Ortega-Pérez G; Alonso-Casado O; Galipienzo-García J; Linero-Noguera MJ; Salvatierra-Díaz D
Surg Oncol Clin N Am; 2018 Jul; 27(3):495-506. PubMed ID: 29935685
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraperitoneal chemotherapy: methodology and safety considerations.
González-Moreno S; González-Bayón L; Ortega-Pérez G
Surg Oncol Clin N Am; 2012 Oct; 21(4):543-57. PubMed ID: 23021715
[TBL] [Abstract][Full Text] [Related]
3. Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kyriazanos I; Kalles V; Stefanopoulos A; Spiliotis J; Mohamed F
Surg Oncol; 2016 Sep; 25(3):308-14. PubMed ID: 27566037
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion.
Glehen O; Cotte E; Kusamura S; Deraco M; Baratti D; Passot G; Beaujard AC; Noel GF
J Surg Oncol; 2008 Sep; 98(4):242-6. PubMed ID: 18726885
[TBL] [Abstract][Full Text] [Related]
5. [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Simon L; Halilou MC; Gladieff L; Gadiou M; Herin F; Hennebelle I; Chatelut E; Ferron G
Bull Cancer; 2009 Oct; 96(10):971-7. PubMed ID: 19762323
[TBL] [Abstract][Full Text] [Related]
6. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
Kusamura S; Dominique E; Baratti D; Younan R; Deraco M
J Surg Oncol; 2008 Sep; 98(4):247-52. PubMed ID: 18726886
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy.
Van der Speeten K; Stuart OA; Sugarbaker PH
Surg Oncol Clin N Am; 2012 Oct; 21(4):577-97. PubMed ID: 23021717
[TBL] [Abstract][Full Text] [Related]
8. Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma.
Elias D; Quenet F; Goéré D
Surg Oncol Clin N Am; 2012 Oct; 21(4):611-23. PubMed ID: 23021719
[TBL] [Abstract][Full Text] [Related]
9. Reported impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Sugarbaker PH
Ann Surg Oncol; 2008 Jun; 15(6):1800-1; author reply 1802-3. PubMed ID: 18196342
[No Abstract] [Full Text] [Related]
10. [Peritoneal carcinomatosis of colorectal cancer: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Königsrainer I; Beckert S; Brücher B; Zieker D; Königsrainer A
Dtsch Med Wochenschr; 2011 Sep; 136(36):1811-4. PubMed ID: 21882140
[TBL] [Abstract][Full Text] [Related]
11. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy.
Younan R; Kusamura S; Baratti D; Cloutier AS; Deraco M
J Surg Oncol; 2008 Sep; 98(4):253-7. PubMed ID: 18726887
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
[TBL] [Abstract][Full Text] [Related]
13. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale.
Roviello F; Caruso S; Neri A; Marrelli D
Eur J Surg Oncol; 2013 Dec; 39(12):1309-16. PubMed ID: 24183797
[TBL] [Abstract][Full Text] [Related]
14. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer.
Braam HJ; Schellens JH; Boot H; van Sandick JW; Knibbe CA; Boerma D; van Ramshorst B
Crit Rev Oncol Hematol; 2015 Sep; 95(3):282-96. PubMed ID: 25921419
[TBL] [Abstract][Full Text] [Related]
15. A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin.
Miailhe G; Arfi A; Mirshahi M; Eveno C; Pocard M; Touboul C
J Visc Surg; 2018 Jun; 155(3):183-189. PubMed ID: 29108718
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for the treatment of peritoneal carcinomatosis in pediatric solid malignancies: a single institution experience.
Bautista F; Elias D; Pasqualini C; Valteau-Couanet D; Brugières L
J Pediatr Surg; 2014 Aug; 49(8):1276-9. PubMed ID: 25092089
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications].
Eveno C; Dagois S; Guillot E; Gornet JM; Pocard M
Bull Cancer; 2008 Jan; 95(1):141-5. PubMed ID: 18230580
[TBL] [Abstract][Full Text] [Related]
18. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.
Helm CW
Surg Oncol Clin N Am; 2012 Oct; 21(4):645-63. PubMed ID: 23021722
[TBL] [Abstract][Full Text] [Related]
19. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
